JP2023030022A5 - - Google Patents

Download PDF

Info

Publication number
JP2023030022A5
JP2023030022A5 JP2022199857A JP2022199857A JP2023030022A5 JP 2023030022 A5 JP2023030022 A5 JP 2023030022A5 JP 2022199857 A JP2022199857 A JP 2022199857A JP 2022199857 A JP2022199857 A JP 2022199857A JP 2023030022 A5 JP2023030022 A5 JP 2023030022A5
Authority
JP
Japan
Prior art keywords
fibrosis
pharmaceutical composition
irap
composition according
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022199857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023030022A (ja
Filing date
Publication date
Priority claimed from JP2020127888A external-priority patent/JP7457360B2/ja
Application filed filed Critical
Publication of JP2023030022A publication Critical patent/JP2023030022A/ja
Publication of JP2023030022A5 publication Critical patent/JP2023030022A5/ja
Pending legal-status Critical Current

Links

JP2022199857A 2015-07-30 2022-12-15 線維症の処置 Pending JP2023030022A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903035 2015-07-30
AU2015903035A AU2015903035A0 (en) 2015-07-30 Fibrotic treatment
JP2020127888A JP7457360B2 (ja) 2015-07-30 2020-07-29 線維症の処置

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020127888A Division JP7457360B2 (ja) 2015-07-30 2020-07-29 線維症の処置

Publications (2)

Publication Number Publication Date
JP2023030022A JP2023030022A (ja) 2023-03-07
JP2023030022A5 true JP2023030022A5 (cg-RX-API-DMAC7.html) 2023-09-29

Family

ID=57883919

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018504650A Withdrawn JP2018527330A (ja) 2015-07-30 2016-07-29 線維症の処置
JP2020127888A Active JP7457360B2 (ja) 2015-07-30 2020-07-29 線維症の処置
JP2022199857A Pending JP2023030022A (ja) 2015-07-30 2022-12-15 線維症の処置

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018504650A Withdrawn JP2018527330A (ja) 2015-07-30 2016-07-29 線維症の処置
JP2020127888A Active JP7457360B2 (ja) 2015-07-30 2020-07-29 線維症の処置

Country Status (8)

Country Link
US (5) US10100311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3328384B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018527330A (cg-RX-API-DMAC7.html)
AU (1) AU2016301113B2 (cg-RX-API-DMAC7.html)
CA (1) CA3017028C (cg-RX-API-DMAC7.html)
HK (1) HK1256423A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201808478RA (cg-RX-API-DMAC7.html)
WO (1) WO2017015720A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11306066B2 (en) * 2015-05-08 2022-04-19 Monash University 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors
WO2017015720A1 (en) * 2015-07-30 2017-02-02 Monash University Fibrotic treatment
CN111163793A (zh) * 2017-07-17 2020-05-15 莫纳什大学 血管紧张素受体激动剂及其用途
JP2022516611A (ja) * 2018-12-28 2022-03-01 ザ ジェネラル ホスピタル コーポレイション 線維性疾患の治療のための抗エフリン-b2遮断抗体
WO2021050089A1 (en) * 2019-09-09 2021-03-18 Washington State University Genetic test for identifying cats at a high risk for developing tubulointerstitial fibrosis
TW202143994A (zh) 2020-02-19 2021-12-01 美商希皮恩製藥公司 環孢素類似物於治療纖維化之用途
WO2023099589A1 (en) * 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Irap inhibitors for use in the treatment of inflammatory diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579768A1 (en) * 2004-09-09 2006-03-16 Howard Florey Institute Of Experimental Physiology And Medicine Enzyme inhibitors and uses thereof
BRPI0615439A2 (pt) * 2005-08-23 2011-05-17 Wyeth Corp métodos para o tratamento de ansiedade e para identificação de agentes ansiolìticos
US8263775B2 (en) * 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
JP2015504870A (ja) * 2011-12-16 2015-02-16 タリックス ファーマシューティカルズ リミテッド 線維症を処置するためのアンジオテンシン
CA2861521A1 (en) * 2012-02-06 2013-08-15 Glaxosmithkline Intellectual Property (No.2) Limited Novel use
JP6327923B2 (ja) 2014-04-25 2018-05-23 旭化成株式会社 ポリアセタール樹脂組成物、及びそれからなる成形体
DE102014114090A1 (de) 2014-09-29 2016-03-31 Karlsruher Institut für Technologie Verfahren zur Abtrennung von Aluminium bei der Calciumsilikatproduktion
US9519061B2 (en) * 2014-12-26 2016-12-13 Here Global B.V. Geometric fingerprinting for localization of a device
US11306066B2 (en) * 2015-05-08 2022-04-19 Monash University 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors
WO2017015720A1 (en) * 2015-07-30 2017-02-02 Monash University Fibrotic treatment

Similar Documents

Publication Publication Date Title
Wang et al. Quercetin dihydrate inhibition of cardiac fibrosis induced by angiotensin II in vivo and in vitro
JP2020189845A5 (cg-RX-API-DMAC7.html)
AU2002328494B2 (en) Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients
AU2016227486A1 (en) Angiotensin ll receptor agonist for treating pulmonary fibrosis
CA2358400A1 (en) Methods for treating conditions associated with the accumulation of excess extracellular matrix
Ergul Endothelin‐1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents
Dell’Aica et al. Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis
SG153831A1 (en) Use of renin inhibitors in therapy
JP2018527330A5 (cg-RX-API-DMAC7.html)
Tan et al. Tryptase promotes the profibrotic phenotype transfer of atrial fibroblasts by PAR2 and PPARγ pathway
JP2009504737A (ja) 脈管疾患の治療又は予防のためのpar−1/par−4阻害剤の使用
US20160175286A1 (en) Selective at2 receptor agonists for use in treatment of cachexia
US20230272021A1 (en) Ccn3 and ccn3 peptides and analogs thereof for therapeutic use
JP2009535330A5 (cg-RX-API-DMAC7.html)
WO2019010482A1 (en) COMPOSITIONS AND METHODS FOR MODULATING COLUMN MATURATION
Paccosi et al. The monocyte chemotactic protein synthesis inhibitor bindarit prevents mesangial cell proliferation and extracellular matrix remodeling
Andersson et al. Fatal acute pancreatitis: Characteristics of patients never reaching hospital
AU2013202269A1 (en) Compositions and methods for the treatment of fibrosis and fibrotic diseases
Shi et al. Apixaban attenuates ischemia-induced myocardial fibrosis by inhibition of Gq/PKC signaling
CN116115763A (zh) 一种含有h1组胺受体拮抗剂的联合用药物
IL293894A (en) Combination treatment of liver diseases using integrin inhibitors
JP2021506268A (ja) 心不全を治療するための改善された化合物
Sasamura et al. Extracellular matrix remodeling in hypertension
US20090202524A1 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
Liu et al. Renal expression of proto-oncogene Ets-1 on matrix remodeling in experimental diabetic nephropathy